A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
Inclusion Criteria:
Exclusion Criteria:
Santa Monica, California 90404, United States
Colorado Springs, Colorado 80909, United States
Miami, Florida 33136, United States
Houston, Texas 77030, United States
Pergamino, Australia
Porto Alegre, Brazil
Paris, France
Bunkyō City, Japan
Hidaka-shi, Japan
Kashiwa-shi, Japan
Kobe, Japan
Kurume-shi, Japan
Osakasayama-shi, Japan
Sunto-gun, Japan
Santiago de Compostela, Spain
Valencia, Spain